儿童急性B淋巴细胞白血病缓解期外周血MDSCs的变化及意义

doi:10.3969/j.issn.1004-616x.2015.06.010

癌变·畸变·突变 ›› 2015, Vol. 27 ›› Issue (6): 454-458.doi: 10.3969/j.issn.1004-616x.2015.06.010

儿童急性B淋巴细胞白血病缓解期外周血MDSCs的变化及意义

熊术道, 王会平, 蒲连芳, 胡林辉, 张翠, 杨冬冬, 翟志敏

安徽医科大学第二附属医院血液内科/血液实验室, 安徽合肥 230601

收稿日期:2015-05-15 修回日期:2015-09-02 出版日期:2015-11-30 发布日期:2015-11-30
作者简介:熊术道,E-mail:xshdao@163.com。
基金资助:
国家自然科学基金(81272259)

The change of MDSCs and its clinical significance in childhood B-lineage acute lymphoblastic leukemia during remission

XIONG Shudao, WANG Huiping, PU Lianfang, HU Linhui, ZHANG Cui, YANG Dongdong, ZHAI Zhimin

Department of Hematology, Hematological Lab, The Second Hospital of Anhui Medical University, Hefei 230601, Anhui, China

Received:2015-05-15 Revised:2015-09-02 Online:2015-11-30 Published:2015-11-30

摘要/Abstract

摘要： 目的:观察儿童急性B淋巴细胞白血病(B-ALL)缓解期患者外周血髓系来源的抑制性细胞(MDSCs)的变化,并探讨其原因及可能的意义。方法:分别抽取22例儿童B-ALL行长春新碱、柔红霉素、左旋门冬酰胺酶和强的松(VDLP)方案化疗后缓解期患者和20例健康体检儿童的外周血,流式细胞术检测和分析CD33⁺HLA-DR^-/CD33⁺细胞比例、以及CD14⁺CD33⁺HLA-DR^-和CD15⁺CD33⁺HLA-DR^-两群MDSCs细胞比例的变化,统计分析B-ALL患者和健康对照组之间MDSCs的差异。结果:儿童B-ALL缓解期患者外周血CD33⁺HLA-DR^-MDSCs所占CD33⁺细胞的比例较健康对照组明显降低(P=0.001);单核细胞来源的CD14⁺CD33⁺HLA-DRMDSCs的比例较健康对照组显著降低(P<0.01);粒细胞来源的CD15⁺CD33⁺HLA-DR^- MDSCs比例亦较健康对照组明显降低(P=0.004)。结论:儿童B-ALL患者行VDLP方案化疗后完全缓解期患者外周血MDSCs的比例明显下降,其低水平的MDSCs可能与化疗后机体免疫系统尚未完全正常建立相关。

关键词: 白血病, 急性白血病, 急性B淋巴细胞白血病, 化疗, 髓系来源的抑制性细胞

Abstract: OBJECTIVE: To investigate the changes,pofential role and cliniral significance of myeloid derived suppressor cells(MDSCs) in the peripheral blood of pediatric patients with B-lineage acute lymphoblastic leukemia(BALL) during remission. METHODS: 22 patients with B-ALL from our hospital treated by VDLP chemotherapy regimen including vincristine,daunorubicin,L-asparaginase and prednisone were selected as the test group during remission,and 20 cases of healthy children were also selected as control group(age and gender-matched). Peripheral blood(PB) were obtained frompatients and controls. Changes of CD33⁺ cells,CD33⁺HLA-DR^- cells,CD14⁺CD33⁺HLADR^- MDSCs and CD15⁺CD33⁺HLA-DR^- MDSCs were examined by flow cytometry,and analyzed statistically wie software of GraphPad Prisms. RESULTS: We found no change of CD33⁺ cells between the patients and control group. However,the ratio of CD33⁺HLA-DR^-/CD33⁺ cells in the patients with B-ALL during remission was lower than that in the healthy control group(P=0.001). The ratio of boe monocyte derived CD14⁺CD33⁺HLA-DR^- MDSCs(P=0.001) and CD15⁺CD33⁺HLA-DR^- MDSCs derived from granulocytes were lower in the healthy control group(P=0.004). CONCLUSION: MDSCs in pediatric patients with B-ALL treated by VDLP regimen during remission was often lower when compared to healthy control,the low level of MDSCs in B-ALL may be associated wie normal immunological system not recovered completely in the remission phase.

Key words: leukemia, acute leukemia, B-ALL, chemotherapy, myeloid derived suppressor cells

中图分类号:

R733.7

熊术道, 王会平, 蒲连芳, 胡林辉, 张翠, 杨冬冬, 翟志敏. 儿童急性B淋巴细胞白血病缓解期外周血MDSCs的变化及意义[J]. 癌变·畸变·突变, 2015, 27(6): 454-458.

XIONG Shudao, WANG Huiping, PU Lianfang, HU Linhui, ZHANG Cui, YANG Dongdong, ZHAI Zhimin. The change of MDSCs and its clinical significance in childhood B-lineage acute lymphoblastic leukemia during remission[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(6): 454-458.

参考文献

[1] Cavassani KA,Carson WF,Moreira AP,et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth[J]. Blood,2010,115(22):4403-4411.
[2] Raychaudhuri B,Rayman P,Ireland J,et al. Myeloidderived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma[J]. Neuro Oncol,2011, 13(6):591-599.
[3] Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy[J]. Clin Cancer Res, 2007,13(18 Sup 1):5243-5248.
[4] Gabrilovich DI,Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol,2009, 9(3):162-174.
[5] Bronte V,Serafini P,Apolloni E,Zanovello P. Tumorinduced immune dysfunctions caused by myeloid suppressor cells[J]. J Immunother,2001,24(6):431-446.
[6] Albeituni SH,Ding C,Yan J. Hampering immune suppressors:therapeutic targeting of myeloid-derived suppressor cells in cancer[J]. Cancer J,2013,19(6):490-501.
[7] Almand B,Clark JI,Nikitina E,et al. Increased production of immature myeloid cells in cancer patients:a mechanism of immunosuppression in cancer[J]. J Immunol,2001,166(1):678-689.
[8] Filipazzi P,Huber V,Rivoltini L. Phenotype,function and clinical implications of myeloid-derived suppressor cells in cancer patients[J]. Cancer Immunol Immunother,2012,61(2):255-263.
[9] Nagaraj S,Youn JI,Weber H,et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer[J]. Clin Cancer Res, 2010,16(6):1812-1823.
[10] Zhang H,Maric I,DiPrima MJ,et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer[J]. Blood,2013,122(7):1105-1113.
[11] Lin Y,Gustafson MP,Bulur PA,et al. Immunosuppressive CD14⁺HLA-DR^low/- monocytes in B-cell non-Hodgkin lymphoma[J]. Blood,2011,117(3):872-8781.
[12] Sander LE,Sackett SD,Dierssen U,et al. Hepatic acutephase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function[J]. J Exp Med,2010,207(7):1453-1464.
[13] Ko JS,Rayman P,Ireland J,et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained[J]. Cancer Res, 2010,70(9):3526-3536.
[14] Montero AJ,Diaz-Montero CM,Kyriakopoulos CE,et al. Myeloid-derived suppressor cells in cancer patients:a clinical perspective[J]. J Immunother,2012,35(2):107-115.
[15] Gorgun GT,Whitehill G,Anderson JL,et al. Tumorpromoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans[J]. Blood,2013,121(15):2975-2987.
[16] Chen MF,Kuan FC,Yen TC,et al. IL-6-stimulated CD11b⁺ CD14⁺HLA-DR^- myeloid-derived suppressor cells,are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus[J]. Oncotarget,2014,5(18):8716-8728.
[17] Rudolph BM,Loquai C,Gerwe A,et al. Increased frequencies of CD11b⁺CD33⁺CD14⁺HLA-DR^low myeloid-derived suppressor cells are an early event in melanoma patients[J]. Exp Dermatol,2014,23(3):202-204.
[18] Huang A,Zhang B,Wang B,et al. Increased CD14⁺HLA-DR^-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients[J]. Cancer Immunol Immunother,2013, 62(9):1439-1451.
[19] Khaled YS,Ammori BJ,Elkord E. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients[J]. J Immunol Res,2014,2014:879897.
[20] Wang Z,Zhang L,Wang H,et al. Tumor-induced CD14⁺HLA-DR^-/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients[J]. Cancer Immunol Immunother, 2015, 64(3):389-399.
[21] Alizadeh D1,Trad M,Hanke NT,et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer[J].Cancer Res,2014,74(1):104-118.
[22] Cripps JG,Gorham JD. MDSC in autoimmunity[J]. Int Immunopharmacol,2011,11(7):789-793.

儿童急性B淋巴细胞白血病缓解期外周血MDSCs的变化及意义

The change of MDSCs and its clinical significance in childhood B-lineage acute lymphoblastic leukemia during remission

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马亚南, 吴楠, 金焰. 肿瘤微环境与卵巢癌化疗耐药机制的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 393-395,400.
[2]	徐启璐, 高慧, 冉学红, 王军军, 张俊英, 刘丽萍. 两种异常核型髓系肿瘤的基因突变及临床相关性分析[J]. 癌变·畸变·突变, 2021, 33(4): 296-301,306.
[3]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[4]	田薇, 方延, 吴晗恬, 吉布强, 夏昭林. 长链非编码RNA与mRNA在急性髓性白血病中的异常表达及其功能初探[J]. 癌变·畸变·突变, 2021, 33(2): 110-115.
[5]	焦文静, 郭秀娟, 马鸣, 邵俊国, 张金艳. 老年局部晚期食管癌同步放化疗与单纯放疗的疗效比较[J]. 癌变·畸变·突变, 2021, 33(2): 124-128.
[6]	伏琼, 唐文娟, 程勇, 贺仁政, 梁冰. 漆姑草醇提物对白血病细胞K562的诱导分化作用[J]. 癌变·畸变·突变, 2021, 33(1): 37-41.
[7]	唐文娟, 伏琼, 程勇, 罗世成, 梁冰. 漆姑草醇提物对人急性早幼粒白血病细胞的诱导分化作用[J]. 癌变·畸变·突变, 2021, 33(1): 42-47.
[8]	万树泉, 魏丽军, 王福花, 曾勇. miR-200b-3p和PAK2 mRNA在耐药卵巢癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2019, 31(3): 216-221.
[9]	杨谨如, 秦露露, 朱勇飞. JAK2基因突变与慢性髓系白血病易感性的meta分析[J]. 癌变·畸变·突变, 2019, 31(3): 231-237.
[10]	吴异兰, 王晗. 白藜芦醇对肺癌紫杉醇耐药细胞的增殖抑制作用及其机制[J]. 癌变·畸变·突变, 2018, 30(3): 200-203,208.
[11]	郭晓, 王蕊, 吴娟, 纪晓坤, 王珩, 张艳, 马阳, 杜芸. 肺腺癌患者新鲜细胞学标本EGFR基因突变检测及意义[J]. 癌变·畸变·突变, 2018, 30(1): 67-70.
[12]	高飞, 王英滨. 贝伐单抗动脉介入超选化疗对大鼠脑胶质瘤的影响[J]. 癌变·畸变·突变, 2018, 30(1): 62-66.
[13]	何曙芝, 赵跃, 刘洋, 杨留才, 陈平, 刘冉. 盐城地区食管癌化疗患者近期生命质量评价[J]. 癌变·畸变·突变, 2017, 29(6): 437-444,449.
[14]	杨兴肖, 马鸣, 单保恩, 李幼梅, 宋姮, 刘志坤, 祝淑钗. 华蟾素注射液对人食管癌细胞增殖、侵袭和化疗敏感性的影响及其机制[J]. 癌变·畸变·突变, 2017, 29(2): 96-101.
[15]	阿衣古丽·哈热, 陆艳荣, 伊斯刊达·阿不力米提, 张瑾熔. 直肠癌新辅助放化疗前后LGR5基因表达的变化及其与疗效的关系[J]. 癌变·畸变·突变, 2017, 29(1): 60-64,69.